highly significantp < 0.001
Stage II patients had OS of 72.7% with ≥12 nodes harvested and 58.3% with <12 nodes ( p = 0.124), and stage III patients had a 5-year OS of 61.5% and 55.6%, respectively ( p = 0.508). In stage III patients, the lymph node ratio (LNR) was highly significant for patient survival, and OS for LNR 1 (<0.25) was 83.3.5%, LNR 2 (0.25–0.50) 63.3%, LNR 3 (0.51–0.75) 18.8%, and LNR 4 (0.76–1) 18.2% (log-rank test p < 0.001).